These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21763682)

  • 21. Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.
    Li Q; Wang W; Machino Y; Yamada T; Kita K; Oshima M; Sekido Y; Tsuchiya M; Suzuki Y; Nan-Ya K; Iida S; Nakamura K; Iwakiri S; Itoi K; Yano S
    Cancer Sci; 2015 Jan; 106(1):102-7. PubMed ID: 25421609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis.
    Martarelli D; Catalano A; Procopio A; Orecchia S; Libener R; Santoni G
    BMC Cancer; 2006 May; 6():130. PubMed ID: 16704740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer agent α-sulfoquinovosyl-acylpropanediol enhances the radiosensitivity of human malignant mesothelioma in nude mouse models.
    Inamasu E; Tsuchiya T; Yamauchi M; Nishi K; Matsuda K; Sugawara F; Sakaguchi K; Mori R; Matsumoto K; Miyazaki T; Hatachi G; Doi R; Watanabe H; Tomoshige K; Matsuda N; Higami Y; Shimokawa I; Nakashima M; Nagayasu T
    J Radiat Res; 2022 Jan; 63(1):19-29. PubMed ID: 34738103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
    Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
    Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
    [No Abstract]   [Full Text] [Related]  

  • 25. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
    Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
    Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
    Usami N; Fukui T; Kondo M; Taniguchi T; Yokoyama T; Mori S; Yokoi K; Horio Y; Shimokata K; Sekido Y; Hida T
    Cancer Sci; 2006 May; 97(5):387-94. PubMed ID: 16630136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
    Servais EL; Colovos C; Rodriguez L; Bograd AJ; Nitadori J; Sima C; Rusch VW; Sadelain M; Adusumilli PS
    Clin Cancer Res; 2012 May; 18(9):2478-89. PubMed ID: 22371455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects.
    Kubota T; Fujiwara H; Amaike H; Takashima K; Inada S; Atsuji K; Yoshimura M; Matsumoto K; Nakamura T; Yamagishi H
    Cancer Sci; 2004 Apr; 95(4):321-7. PubMed ID: 15072590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
    Harada A; Uchino J; Harada T; Nakagaki N; Hisasue J; Fujita M; Takayama K
    Cancer Sci; 2017 Jan; 108(1):116-123. PubMed ID: 27783867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor.
    Keshava S; Sahoo S; Tucker TA; Idell S; Rao LV; Pendurthi UR
    Cancer Res; 2013 Jul; 73(13):3963-73. PubMed ID: 23539451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
    Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
    Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.
    Ohta Y; Shridhar V; Kalemkerian GP; Bright RK; Watanabe Y; Pass HI
    Cancer; 1999 Jun; 85(12):2570-6. PubMed ID: 10375104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.
    Abe S; Morita Y; Kaneko MK; Hanibuchi M; Tsujimoto Y; Goto H; Kakiuchi S; Aono Y; Huang J; Sato S; Kishuku M; Taniguchi Y; Azuma M; Kawazoe K; Sekido Y; Yano S; Akiyama S; Sone S; Minakuchi K; Kato Y; Nishioka Y
    J Immunol; 2013 Jun; 190(12):6239-49. PubMed ID: 23690472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma.
    Otsuki T; Nakashima T; Hamada H; Takayama Y; Akita S; Masuda T; Horimasu Y; Miyamoto S; Iwamoto H; Fujitaka K; Miyata Y; Miyake M; Kohno N; Okada M; Hattori N
    Eur Respir J; 2018 May; 51(5):. PubMed ID: 29519924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
    Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
    Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
    Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
    Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
    Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
    Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.